Malvern Institute

Stay Connected With Malvern. Get Email Updates

info@malverninstitute.com | Follow Us:

Local woman testifies about Big Pharma’s role in daughter’s overdose death

September 13, 2017 – Local communities and families are standing up against pharmaceutical companies for misleading patients about the dangerous effects of opioids.

According to philly.com, the U.S. Senate held a hearing about the marketing practices of the pharmaceutical industry.

Deborah Fuller, of Cherry Hill, shared her thoughts that Insys Therapeutics Inc. contributed to the overdose death of her daughter, 32-year-old Sarah Fuller.

Malvern Institute operates an outpatient center in Cherry Hill, located at 401 Kings Highway, Building #1.

Her mother, Deborah, described listening to an audio recording in which a drug company representative falsely said she was from Sarah’s doctor’s office and misled a pharmacy benefits manager into believing that Sarah had breakthrough cancer pain. That’s the only condition that Insys’ fast-acting fentanyl brand, Subsys, was approved to treat.

“Every day of my life, I must live with the realization that Sarah is gone because of Insys’ greed,” Fuller said. “I believe that Sarah’s death certificate should be changed to indicate her death was a homicide and the cause of death should be changed to ‘corporate greed.’”

If you or a loved one are living with addiction and have any questions about the Malvern Intervention Services or the Malvern 90-Day Model, please give us a call at 610.MALVERN (610.625.8376).

Read the full story on philly.com.

Testimonials

Recent News

Podcast tackles science behind addiction treatment, opioid epidemic

March 30, 2018 – Raising awareness of the facts about the disease of addiction and breaking the stigma associated with addiction are necessary steps toward truly helping families affected by the disease of addiction. This month, Gimlet Media’s “Science Vs.” podcast released two episodes dedi...

Read More

See All News

© 2017 Malvern Institute - All Rights Reserved | View Privacy Policy